Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-alpha and interleukin-1 beta by peripheral blood monocytes in the acute phase of Kawasaki disease.

Literature DB >> 8777922

Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-alpha and interleukin-1 beta by peripheral blood monocytes in the acute phase of Kawasaki disease.

H Suzuki¹, S Uemura, S Tone, T Iizuka, M Koike, K Hirayama, J Maeda.

Abstract

In order to study the in vitro effects of intact immunoglobulin (Ig) and gamma-interferon (INF-gamma) in patients with Kawasaki disease, the production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta) was measured in peripheral blood monocytes (PBM) both before and after intravenous immunoglobulin (IVIG) therapy. Spontaneous production of TNF-alpha and IL-1 beta both before and after IVIG therapy was significantly higher than in healthy controls. Intact Ig enhanced in vitro the production of TNF-alpha and IL-1 beta both before and after IVIG therapy approximately 3-4 times as compared to the spontaneous production. INF-gamma did not affect the production of the two cytokines. Ig enhanced IL-1 beta mRNA expression in PBM of KD by 3-8 times more than that of spontaneous production.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1996 PMID： 8777922 DOI： 10.1007/bf02002715

Source DB: PubMed Journal: Eur J Pediatr ISSN： 0340-6199 Impact factor: 3.183

24 in total

1. The treatment of Kawasaki syndrome with intravenous gamma globulin.

Authors: J W Newburger; M Takahashi; J C Burns; A S Beiser; K J Chung; C E Duffy; M P Glode; W H Mason; V Reddy; S P Sanders
Journal: N Engl J Med Date: 1986-08-07 Impact factor: 91.245

2. Intravenous gamma globulin therapy in Kawasaki disease--trial of low dose gamma globulin.

Authors: M Okuni; K Harada; H Yamaguchi; H Yanagawa; T Sonobe; T Kawasaki
Journal: Prog Clin Biol Res Date: 1987

Review 3. Clinical uses of intravenous immunoglobulins.

Authors: S A Berkman; M L Lee; R P Gale
Journal: Ann Intern Med Date: 1990-02-15 Impact factor: 25.391

Review 4. Putative mechanisms of the effect of intravenous gamma-globulin.

Authors: F S Rosen
Journal: Clin Immunol Immunopathol Date: 1993-06

5. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors: T Kawasaki
Journal: Arerugi Date: 1967-03

6. Spontaneous tumor necrosis factor production in Kawasaki disease.

Authors: B A Lang; E D Silverman; R M Laxer; A S Lau
Journal: J Pediatr Date: 1989-12 Impact factor: 4.406

7. Urinary neopterin as a predictive marker of coronary artery abnormalities in Kawasaki syndrome.

Authors: T Iizuka; Y Minatogawa; H Suzuki; M Itoh; S Nakamine; Y Hatanaka; S Uemura; M Koike
Journal: Clin Chem Date: 1993-04 Impact factor: 8.327

8. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo.

Authors: P Aukrust; S S Frøland; N B Liabakk; F Müller; I Nordøy; C Haug; T Espevik
Journal: Blood Date: 1994-10-01 Impact factor: 22.113

9. Intravenous immunoglobulin induces interferon-gamma and interleukin-6 in vivo.

Authors: Z D Ling; E Yeoh; B T Webb; K Farrell; J Doucette; D S Matheson
Journal: J Clin Immunol Date: 1993-09 Impact factor: 8.317

10. High-dose intravenous gammaglobulin for Kawasaki disease.

Authors: K Furusho; T Kamiya; H Nakano; N Kiyosawa; K Shinomiya; T Hayashidera; T Tamura; O Hirose; Y Manabe; T Yokoyama
Journal: Lancet Date: 1984-11-10 Impact factor: 79.321

17 in total

1. Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease.

Authors: Youngho Lee; Danica J Schulte; Kenichi Shimada; Shuang Chen; Timothy R Crother; Norika Chiba; Michael C Fishbein; Thomas J A Lehman; Moshe Arditi
Journal: Circulation Date: 2012-02-23 Impact factor: 29.690

2. IL-1 Signaling Is Critically Required in Stromal Cells in Kawasaki Disease Vasculitis Mouse Model: Role of Both IL-1α and IL-1β.

Authors: Youngho Lee; Daiko Wakita; Jargalsaikhan Dagvadorj; Kenichi Shimada; Shuang Chen; Ganghua Huang; Thomas J A Lehman; Michael C Fishbein; Hal M Hoffman; Timothy R Crother; Moshe Arditi
Journal: Arterioscler Thromb Vasc Biol Date: 2015-10-29 Impact factor: 8.311

3. Impairment of Left Ventricular Longitudinal Contraction is Associated with Serum Brain Natriuretic Peptide Concentration in Patients with Acute-Phase Kawasaki Disease.

Authors: Ikuo Hashimoto; Kazuhiro Watanabe; Mako Okabe; Hisashi Kaneda
Journal: Pediatr Cardiol Date: 2015-01-28 Impact factor: 1.655

4. Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment.

Authors: M Gupta; G J Noel; M Schaefer; D Friedman; J Bussel; R Johann-Liang
Journal: J Clin Immunol Date: 2001-05 Impact factor: 8.317

Review 5. Treatment Options for Resistant Kawasaki Disease.

Authors: Linny Kimly Phuong; Nigel Curtis; Peter Gowdie; Jonathan Akikusa; David Burgner
Journal: Paediatr Drugs Date: 2018-02 Impact factor: 3.022

6. Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial.

Authors: Michael A Portman; Nagib S Dahdah; April Slee; Aaron K Olson; Nadine F Choueiter; Brian D Soriano; Sujatha Buddhe; Carolyn A Altman
Journal: Pediatrics Date: 2019-05-02 Impact factor: 7.124

7. Brain natriuretic peptide as a hormonal marker of ventricular diastolic dysfunction in children with Kawasaki disease.

Authors: S Kurotobi; N Kawakami; K Shimizu; H Aoki; S Nasuno; K Takahashi; S Kogaki; K Ozono
Journal: Pediatr Cardiol Date: 2005 Jul-Aug Impact factor: 1.655